SAN FRANCISCO--(BUSINESS WIRE)--Fluxion Biosciences, a leading developer of microfluidic systems for cellular analysis in life sciences research, today announced that it has received an NIH grant for the development of a high throughput screening platform for anti-microbial drug discovery. The Phase I NIH grant will enable the Company to further develop its innovative microfluidic platform for cellular research and drug discovery.
